Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer

Gastric Cancer

Volumn 17, Issue 2, 2014, Pages 383-386

  Takahari, Daisuke ^a   Hamaguchi, Tetsuya ^b   Yoshimura, Kenichi ^c   Katai, Hitoshi ^b   Ito, Seiji ^a   Fuse, Nozomu ^d   Konishi, Masaru ^d   Yasui, Hirofumi ^e   Terashima, Masanori ^e   Goto, Masahiro ^f   Tanigawa, Nobuhiko ^f   Shirao, Kuniaki ^g   Sano, Takeshi ^h   Sasako, Mitsuru ⁱ  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g OITA UNIVERSITY   (Japan)

^h CANCER INSTITUTE HOSPITAL   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; Cisplatin; Gastric cancer; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; DRUG COMBINATION; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG COMBINATIONS; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXONIC ACID; PERITONEAL NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 84898802807     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0264-8     Document Type: Article

References (6)

1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20. (Pubitemid 350044801)
2. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-93.
3. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-21.
4. Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, et al. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67:1423-8.
5. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1998;1:10-24.
6. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-21.